Biosimilar biologic drugs: a new frontier in medical care. Issue 4 (19th May 2017)

• Record Type: Journal Article
• Authors: Geynisman, Daniel M.; De Velasco, Guillermo; Sewell, K. Lea; Jacobs, Ira
• Is Part Of: Postgraduate medicine. Volume 129:Issue 4(2017)
• Page Start: 460
• Page End: 470
• Publication Date: 2017-05-19
• Subjects: Biosimilars -- biologic therapy -- drug development -- regulatory approval; Medicine -- Periodicals; Medicine -- Periodicals; Medicine; Periodicals; 610.5
• DOI: 10.1080/00325481.2017.1311196
• Languages: English
• ISSNs: 0032-5481

Abstract

ABSTRACT: Physicians in training are expected to be aware of the newest developments in patient care. Biologic therapies have changed treatment of many diseases by specifically targeting key disease mediators, but patient access to these therapies can be limited. As patents for the first biologic therapies are expiring, the development and approval of products known as biosimilars is rapidly gaining momentum. A biosimilar is a biologic product that is highly similar to a reference product (a licensed biologic product), notwithstanding minor differences in clinically inactive components. Biosimilars undergo a thorough evaluation compared with the licensed biologic and need to demonstrate comparable clinical pharmacokinetics, efficacy, and safety including immunogenicity. Understanding the processes for new drug approvals, the rigorous evaluation of biosimilars, and considerations about their selection and use can help recently trained physicians to make informed treatment decisions and improve patient outcomes.